

- AHPBP. *J. Clin. Oncol.* 1988; **6**: 762-768.
8. Harvey, H.A. The management of hypercalcemia of malignancy. *Support. Care Cancer* 1995; **3**: 123-129.
 9. Cantwell, B.M.J., Harris, A.L. Effect of single high dose infusion of aminohydroxypropylidene diphosphonate on hypercalcemia caused by cancer. *Br. Med. J.* 1987; **294**: 467-469.
 10. Ralston, S.H., Alzaid, A.A., Gallacher, S.J., Gardner, M.D., Cowan, R.A., Boyle, I.T. Clinical experience with aminohydroxypropylidene bisphosphonate (APD) in the management of Cancer-associated hypercalcemia. *Quart. J. Med.* 1988; **258**: 825-834.
 11. Body, J.J. Medical treatment of tumor-induced hypercalcemia and tumor-induced osteolysis: challenges for future research. *Support Care Cancer* 1993; **1**: 26-33.
 12. Body, J.J., Borkowski, A., Cleeren, A., Bijvoet, O.L.M.. Treatment of malignancy associated hypercalcemia with intravenous aminohydroxy-propylidene diphosphonate (APD). *J Clin Oncol* 1986; **4**: 1177-1183.
 13. Gurney, H., Grill, V., Mann, T.J. Parathyroid hormone-related protein and response to pamidronate in tumor-induced hypercalcemia. *Lancet* 1993; **341**: 1611-1613.
 14. Body, J.J., Dumon, J.C., Thirion, M., Cleeren, A. Circulating PTH-rp concentrations in tumor-induced hypercalcemia: influence on the response to bisphosphonate and changes after therapy. *J. Bone Miner. Res.* 1993; **8**: 701-706.

REFERENCES

1. Fisher, R.A., Helfrich, D.A., Bold, S.M. Hypercalcemia of malignancy: a review. *Support. Care Cancer* 1995; **3**: 123-129.
2. Wimalawansa, S.J. Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate. *Cancer* 1994; **73**: 2222-2230.
3. Ralston, S.H., Gallacher, S.J., Patel, U., Durburgh, F.J., Fraser, W.D., Cowan, R.A., et al. Comparison of three intravenous bisphosphonates in cancer-associated hypercalcemia. *Lancet* 1987; **11**: 1180-1182.
4. Pecherstorfer, M., Thiebaud, D. Treatment of resistant tumor-induced hypercalcemia with escalating doses of pamidronate (APD). *Ann Oncol* 1992; **3**: 661-663.
5. Gucaalp, R., Risch, P., Wiemik, F.H., Sauer, P.R., Keller, A., Richman, S.P., et al. Comparative study of pamidronate disodium and etidronate in the treatment of cancer-related hypercalcemia. *J. Clin. Oncol.* 1992; **10**: 134-142.
6. Purohit, O.P., Radstone, C.R., Anthony, C., Kaur, J.A., Coleman, R.E. A randomized double-blind comparison of intravenous pamidronate and etidronate in the hypercalcemia of malignancy. *Br. J. Cancer* 1992; **73**: 1289-1293.
7. Thiebaud, D., Jager, P.H., Jaquet, A.F., Buckhardt, B. Dose response in the treatment of hypercalcemia of malignancy by a single infusion of the diphosphonate pamidronate. *Support Care Cancer* 1993; **1**: 26-33.